Skip to content

Study · Not a test of the peptide alone · 2023

3 results

Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.

Ito K, Satoh S, Kondo Y, Tamura H, Hasebe M, Terauchi Y

Diabetology international13 Jul 2022

PMID36636162 (opens in a new tab)PMCIDPMC9829941 (opens in a new tab)DOI10.1007/s13340-022-00592-z (opens in a new tab)PepBankPUB-36636162
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In patients with type 2 diabetes, HbA1c decreased from baseline after 4, 12, and 24 weeks of dulaglutide plus long-acting insulin.

    In plain wordsIn patients with diabetes, the combination reduced HbA1c from baseline at each reported visit.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c over follow-up
    Study

    n = 20

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −2.2%
    4 weeks
    HbA1c change
    −3.7%
    12 weeks
    HbA1c change
    −3.6%
    24 weeks

    Source sentences

    Summary
    Hemoglobin A1c levels were significantly reduced after 4, 12, and 24 weeks of combination therapy (- 2.2% ± 0.4%, P P = 0.0003; and - 3.6% ± 0.8%, P = 0.0005, respectively).
    1 context sentence
    Summary · context
    This retrospective observational study included 20 patients with type 2 diabetes who underwent blood glucose management with intensive insulin therapy for a limited period. All patients were switched from intensive insulin therapy to combination therapy comprising dulaglutide and long-acting insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In patients with type 2 diabetes, glycemic variability decreased from baseline after 1 and 24 weeks of dulaglutide plus long-acting insulin.

    In plain wordsIn patients with diabetes, the combination reduced blood glucose fluctuations from baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlycemic variability
    Study

    n = 20

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glycemic variability (% CV) change
    −5.7%
    1 week
    Glycemic variability (% CV) change
    −8.7%
    24 weeks

    Source sentences

    Summary
    Glycemic variability (% coefficient of variation) was significantly decreased after 1 and 24 weeks of combination therapy (- 5.7% ± 2.1%, P = 0.011; and - 8.7% ± 2.4%, P = 0.003, respectively)
    1 context sentence
    Summary · context
    This retrospective observational study included 20 patients with type 2 diabetes who underwent blood glucose management with intensive insulin therapy for a limited period. All patients were switched from intensive insulin therapy to combination therapy comprising dulaglutide and long-acting insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In patients with diabetes, readings and time above 250 mg/dL decreased from baseline at 24 weeks of dulaglutide plus long-acting insulin.

    In plain wordsIn patients with diabetes, the combination reduced very high glucose readings and time from baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseReadings and time above glucose threshold
    Study

    n = 20

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Readings and time >250 mg/dL change
    −2.2%
    24 weeks

    Source sentences

    Summary
    and the percentage of readings and time > 250 mg/dL at 24 weeks was significantly improved (- 2.2% ± 0.8%, P = 0.019).
    1 context sentence
    Summary · context
    This retrospective observational study included 20 patients with type 2 diabetes who underwent blood glucose management with intensive insulin therapy for a limited period. All patients were switched from intensive insulin therapy to combination therapy comprising dulaglutide and long-acting insulin.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.